The patent application for the new coronavirus vaccine (Ad5-nCoV vaccine) developed jointly by Chen Wei from the Military Medical Research Academy of the Chinese Academy of Military Sciences and CanSino Biosciences Company has been approved. This was China's first patent for the novel coronavirus. The patent document filed on March 18th was approved on August 11th.
Chen Wei, a member of the team that developed the vaccine, was given the title of "People's Hero" on August 11. The recombinant novel coronavirus vaccine developed by the team led by Chen Wei has completed the 1st stage clinical trial in the country and the 2nd phase clinical trial in the world. Thus, the safety of the vaccine and whether it enhances immunity was confirmed. The 3rd phase international clinical trial of the vaccine is progressing steadily.
The recombinant novel coronavirus vaccine, jointly developed by CanSino and the Military Medical Academy Bioengineering Institute, will be a stock vaccine on the market. The public offering of the vaccine is also remarkable. On the first day of CanSino's official public offering, there was an 87,45 percent increase.
Hibya News Agency